Literature DB >> 1317234

Oral administration of carvedilol and prazosin inhibits the prostaglandin F2 alpha- and noradrenaline-induced contraction of human hand veins in vivo.

C Beermann1, J Schloos, G G Belz.   

Abstract

Carvedilol is a beta-blocker with additional vasodilating activity. This study was performed in order to determine whether the vasodilator action of orally administered carvedilol in man is based upon an alpha-adrenoceptor antagonism exclusively or if evidence for an additional mechanism could be confirmed. The influence of carvedilol (50 mg p.o.) and prazosin (2 mg p.o.) upon the vasoconstrictor effect of noradrenaline and prostaglandin F2 alpha, infused into superficial hand veins, was established in 8 healthy male volunteers. Increasing dosages of the vasoconstrictors below their threshold of systemic activity were employed in order to obtain dose-response curves of the hand veins congested at a venous occlusion pressure of 40 mmHg. These dose-response curves were repeated 1 and 3.5 h after oral administration of either carvedilol, prazosin, or placebo. The ex vivo, in vitro alpha 1-receptor occupancy in plasma was measured before and after each vasoconstrictor dose-response curve, using an alpha 1-radioreceptor binding assay. Washout periods of 48 h were kept between study days, investigating the influence of one orally administered drug upon one of the local vasoconstrictor dose-response curves at a time. In the alpha 1-radioreceptor assay, plasma concentrations from 0.9- to 1.7-fold the equilibrium dissociation constant (Ki) of carvedilol could be evaluated 1 as well as 3.5 h after medication, corresponding with a receptor occupancy of 44%-63%. After prazosin, 9-13 times the Ki values were determined, which amounts to an alpha 1-adrenoceptor occupation of about 90%-93%.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1317234     DOI: 10.1007/bf00207606

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  19 in total

1.  Pharmacokinetics and disposition of carvedilol in humans.

Authors:  G Neugebauer; W Akpan; E von Möllendorff; P Neubert; K Reiff
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

2.  Effect of catecholamines and other vasoactive substances on superficial hand veins in man.

Authors:  J G Collier; C Nachev; B F Robinson
Journal:  Clin Sci       Date:  1972-09       Impact factor: 6.124

3.  Changes in compliance of peripheral veins after myocardial infarction.

Authors:  B F Robinson; C Nachev; J Collier
Journal:  Br Heart J       Date:  1970-07

Review 4.  The pharmacologic basis of antihypertensive therapy: The role of vasodilator drugs.

Authors:  C A Chidsey; T B Gottlieb
Journal:  Prog Cardiovasc Dis       Date:  1974 Sep-Oct       Impact factor: 8.194

5.  A new technique for recording compliance of human hand veins.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

6.  Evidence for separate PGD2 and PGF2 alpha receptors in the canine mesenteric vascular bed.

Authors:  L P Feigen; B M Chapnick
Journal:  Prostaglandins       Date:  1979-08

7.  Modulation of autonomic neurotransmission by PGD2: comparison with effects of other prostaglandins in anesthetized cats.

Authors:  D P Hemker; J W Aiken
Journal:  Prostaglandins       Date:  1980-08

8.  Clinical pharmacology of carvedilol in normal volunteers.

Authors:  L X Cubeddu; N Fuenmayor; F Varin; V G Villagra; R E Colindres; J R Powell
Journal:  Clin Pharmacol Ther       Date:  1987-01       Impact factor: 6.875

9.  Beta-adrenoceptors in the human dorsal hand vein, and the effects of propranolol and practolol on venous sensitivity to noradrenaline.

Authors:  C B White; B P Udwadia
Journal:  Br J Clin Pharmacol       Date:  1975-04       Impact factor: 4.335

10.  The action of prazosin in human vascular preparations.

Authors:  R A Jauernig; R F Moulds; J Shaw
Journal:  Arch Int Pharmacodyn Ther       Date:  1978-01
View more
  3 in total

Review 1.  Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  C J Dunn; A P Lea; A J Wagstaff
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 2.  Clinical pharmacology, physiology and pathophysiology of superficial veins--2.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

Review 3.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.